Media headlines about Rockwell Medical (NASDAQ:RMTI) have been trending somewhat positive on Friday, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Rockwell Medical earned a news sentiment score of 0.04 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 47.081363981662 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:

A number of equities analysts have commented on the stock. BidaskClub upgraded shares of Rockwell Medical from a “strong sell” rating to a “sell” rating in a research note on Friday, August 11th. Zacks Investment Research downgraded shares of Rockwell Medical from a “hold” rating to a “sell” rating in a research note on Tuesday, August 15th. Ifs Securities assumed coverage on shares of Rockwell Medical in a research note on Monday, August 14th. They issued a “strong-buy” rating and a $11.00 target price on the stock. Finally, ValuEngine downgraded shares of Rockwell Medical from a “hold” rating to a “sell” rating in a research note on Friday, June 2nd. Three analysts have rated the stock with a sell rating, one has given a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. Rockwell Medical currently has an average rating of “Hold” and a consensus target price of $8.38.

Shares of Rockwell Medical (RMTI) traded up 0.30% during trading on Friday, reaching $6.65. 123,592 shares of the company’s stock were exchanged. The stock’s market cap is $344.07 million. Rockwell Medical has a 12-month low of $3.55 and a 12-month high of $8.98. The company has a 50 day moving average of $7.00 and a 200 day moving average of $6.94.

Rockwell Medical (NASDAQ:RMTI) last posted its quarterly earnings results on Wednesday, August 9th. The company reported ($0.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by $0.04. Rockwell Medical had a negative net margin of 39.68% and a negative return on equity of 42.22%. The business had revenue of $13.24 million during the quarter, compared to analysts’ expectations of $13.05 million. During the same quarter in the previous year, the business posted ($0.11) EPS. The company’s quarterly revenue was down 1.6% on a year-over-year basis. Equities research analysts anticipate that Rockwell Medical will post ($0.44) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Rockwell Medical (RMTI) Receiving Somewhat Favorable Media Coverage, Study Shows” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/08/25/rockwell-medical-rmti-receiving-somewhat-favorable-media-coverage-study-shows.html.

About Rockwell Medical

Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.

Insider Buying and Selling by Quarter for Rockwell Medical (NASDAQ:RMTI)

Receive News & Stock Ratings for Rockwell Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical Inc. and related stocks with our FREE daily email newsletter.